# Low-dose Temozolomide for 2 Weeks on Brain Tumor Enzyme in Patients With Gliomas (P04602 AM1) (Completed)

> **NCT00424554** · PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 40 (actual)

## Conditions studied

- Glioma

## Interventions

- **DRUG:** temozolomide

## Key facts

- **NCT ID:** NCT00424554
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-09-26
- **Primary completion:** 2010-01-11
- **Final completion:** 2011-02-16
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2017-06-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00424554

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00424554, "Low-dose Temozolomide for 2 Weeks on Brain Tumor Enzyme in Patients With Gliomas (P04602 AM1) (Completed)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00424554. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*